Beyond the Buzz Into the Core
Shares of Sun Pharmaceuticals, India’s largest drug manufacturer, gained more than 50% over the last one year. In its latest results, the company also posted a 34% on year jump in Q4 profit. While the stock did decline slightly this week, pharma analysts are positive on the stock as the company has shown growth across key therapies. The biggest reason for optimism is Sun Pharma’s global specialty business, which exceeded USD1 billion in sales in
Illustration by Sadhana Saxena via AI. Synopsis Advent, which merged Suven Pharma with Cohance Lifesciences in February, looks to take advantage of the China+1 wave and other geopolitical tailwinds. While the skills of its scientists give India an edge in pharma outsourcing, the scale of local contract manufacturers pales in front of global rivals from […]
Sudhir Srivastava (centre) with his expanding team at SS Innovations; image credit: SS Innovations Synopsis In an exclusive interaction with ET Prime, cardiac surgeon Sudhir Prem Srivastava, the man behind 1,500 successful robotic surgeries, discusses his eventful journey. He details the concept, design and instrumentation of five-armed Mantra, the robotic surgery system, and the dire […]
Is the pharma market, which is currently at INR2.17 lakh crore (USD25.8 billion), getting too crowded? While some industry experts believe a few clear signs of fatigue have emerged, many say it is not a doom scenario yet and a rebound may not be far.